First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal Mesothelioma | MicrobiomeTrials← Back to trialsNCT07893340
First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal Mesothelioma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-10-30Est. Completion: 2028-06-30
Enrollment target: 19 participants Locations- Fudan University ShangHai Cancer Center, Shanghai, Shanghai Municipality, China
Other microbiome trials you might be interested in
Peritoneal Malignant Mesothelioma
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy…
Phoenix, United StatesEst. completion Aug 1, 2027
ThymomaStomach NeoplasmsPancreatic NeoplasmsMesotheliomaBiliary Tract NeoplasmsMesothelin Expressing Neoplasms
Background:
* Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, peri…
Bethesda, United StatesEst. completion Jul 25, 2033